An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s486562 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Yang Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijin…. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 2-Ring, Thiadiazoles. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
- Astellas Pharma Global Development, Inc, Northbrook, IL, USA.
- Astellas Pharma Inc, Tokyo, Japan.
- Astellas (China) Investment Co, Ltd, Beijing, People's Republic of China.
ORCID-Profile: Aixin Shi
Zitieren
APA
Li, Y., Liu, Y., Iwai, M., Takeuchi, M., Song, N., Li, Y., & Shi, A. (2025). An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s486562
Vancouver
Li Y, Liu Y, Iwai M, Takeuchi M, Song N, Li Y, et al. An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s486562
BibTeX
@article{Li2025,
author = {Li, Yang and Liu, Yue and Iwai, Megumi and Takeuchi, Masato and Song, Nan and Li, Yuan and Shi, Aixin},
title = {An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s486562}
}
EUVIMED